In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies. AHA also called for policies to increase transparency in drug pricing; provide rebates to Medicare when a drug’s average manufacturer or sales price exceeds inflation; better align incentives in the Part D reinsurance program; and protect the 340B Drug Pricing Program. 

Related News Articles

Headline
AHA today released its advocacy agenda for the coming year, which details the association’s key priorities for Congress, the Administration, regulatory…
Chairperson's File
For the past 125 years, the AHA has been a tireless advocate for the health care field, patients and communities. We need this diligent work and bold…
Headline
The Centers for Medicare & Medicaid Services yesterday released a memo and timeline outlining how it will approach implementing the Inflation…
Headline
The Department of Health and Human Services Office of Civil Rights yesterday announced a proposed rule with changes to the process for handling conscience…
Headline
President Biden late Thursday signed into law the $1.7 trillion omnibus bill that will keep the government funded through September 2023. H.R. 2617, the “…
Headline
The Department of Homeland Security Dec. 19 released policy guidance for the Public Charge Ground of Inadmissibility final rule. The final rule excluded…